Roche expands use of Ventana PD-L1 assay in CE markets
Ventana PD-L1 (SP142) assay was developed to enhance visual contrast of tumour-infiltrating immune cell staining
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Ventana PD-L1 (SP142) assay was developed to enhance visual contrast of tumour-infiltrating immune cell staining
The research study is aimed at understanding the role of the autonomic nervous system in depression and coronary…
OCT has become crucial in detection and monitoring of key retinal pathologies including Choroidal Neovascularization, Diabetic Retinopathy, microaneurysms
BioTek acquisition expands Agilent's presence and expertise in cell analysis and strengthens its position in immuno-oncology and immunotherapy…
Philips IntelliSite Pathology Solution is designed for in-vitro diagnostic purposes
The suture fixation points in the Ahmed ClearPath implant are positioned more anteriorly on the device compared to…
Cancer biomarkers are molecules that are exclusively found in cancer cells and are over-expressed in cancer cells than…
The cloud-based IntelliSpace Connect data management solution helps set the stage for coordinated care across the patient’s clinical…
FDA has approved the Sapien 3 and Sapien 3 Ultra for Edwards Lifesciences, and the CoreValve Evolut R…
Multiple clinical studies on the skin closure device have demonstrated significant time saving, fewer wound complications and the…